Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
Identifieur interne : 000678 ( Main/Exploration ); précédent : 000677; suivant : 000679Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
Auteurs : Russell C. Callaghan [Canada] ; James K. Cunningham [États-Unis] ; Gautam Sajeev [Canada] ; Stephen J. Kish [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-10-30.
English descriptors
Abstract
Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23263
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title><author><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name></author><author><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name></author><author><name sortKey="Sajeev, Gautam" sort="Sajeev, Gautam" uniqKey="Sajeev G" first="Gautam" last="Sajeev">Gautam Sajeev</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2953724CA123F4AB4F11A4E7F19C3173786C0FCF</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23263</idno><idno type="url">https://api.istex.fr/document/2953724CA123F4AB4F11A4E7F19C3173786C0FCF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002630</idno><idno type="wicri:Area/Main/Curation">002290</idno><idno type="wicri:Area/Main/Exploration">000678</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders</title><author><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Family and Community Medicine, The University of Arizona, Tucson, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Sajeev, Gautam" sort="Sajeev, Gautam" uniqKey="Sajeev G" first="Gautam" last="Sajeev">Gautam Sajeev</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Social, Epidemiological Research Department, Centre for Addiction and Mental Health, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Departments of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-10-30">2010-10-30</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2333">2333</biblScope><biblScope unit="page" to="2339">2339</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">2953724CA123F4AB4F11A4E7F19C3173786C0FCF</idno><idno type="DOI">10.1002/mds.23263</idno><idno type="ArticleID">MDS23263</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>incidence</term><term>longitudinal</term><term>methamphetamine</term><term>parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Arizona</li><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name></noRegion><name sortKey="Callaghan, Russell C" sort="Callaghan, Russell C" uniqKey="Callaghan R" first="Russell C." last="Callaghan">Russell C. Callaghan</name><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><name sortKey="Sajeev, Gautam" sort="Sajeev, Gautam" uniqKey="Sajeev G" first="Gautam" last="Sajeev">Gautam Sajeev</name></country><country name="États-Unis"><region name="Arizona"><name sortKey="Cunningham, James K" sort="Cunningham, James K" uniqKey="Cunningham J" first="James K." last="Cunningham">James K. Cunningham</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000678 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000678 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2953724CA123F4AB4F11A4E7F19C3173786C0FCF
|texte= Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
}}
| This area was generated with Dilib version V0.6.23. |  |